Chemotherapy Provides Longer Survival than Enzyme Therapy for Pancreatic Cancer
In a clinical trial testing an experimental enzyme regimen against gemcitabine-based chemotherapy for advanced pancreatic cancer, people receiving chemotherapy lived an average of 9.7 months longer. The results are published in the Journal of Clinical Oncology.
People in the chemotherapy group received treatment on a schedule chosen by their treating physician. Those in the experimental group received pancreatic enzyme pills and nutritional supplements, ate a strict organic diet, and underwent a detoxification program. People in the experimental group survived for an average of 4.3 months after beginning treatment, compared to 14 months in the chemotherapy group.
♦ ♦ ♦ ♦ ♦
This article was originally published in Coping® with Cancer magazine, November/December 2009.